# Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

> **NCT03452397** · PHASE2 · COMPLETED · sponsor: **Oyster Point Pharma, Inc.** · enrollment: 165 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
- **DRUG:** 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
- **DRUG:** 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
- **DRUG:** Placebo (vehicle) nasal spray

## Key facts

- **NCT ID:** NCT03452397
- **Lead sponsor:** Oyster Point Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-27
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-04-27
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452397, "Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03452397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*